Actively Recruiting
Correlation Between PLA Levels and Disease Severity in Patients With Sepsis Cardiac Insufficiency
Led by Dongzhimen Hospital, Beijing · Updated on 2024-10-23
30
Participants Needed
1
Research Sites
139 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Sepsis cardiac insufficiency is characterized by high morbidity and mortality. Studies have shown an association between elevated PLA levels in patients with sepsis and clinical outcomes of cardiac dysfunction. This study will explore the correlation between circulating PLA levels and organ dysfunction and disease severity in SIMD patients in the form of a cross-sectional study.
CONDITIONS
Official Title
Correlation Between PLA Levels and Disease Severity in Patients With Sepsis Cardiac Insufficiency
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosis of sepsis cardiac insufficiency
- Hospitalized in the first ICU area of Dongzhimen Hospital between April 2024 and December 2026
- Age between 50 and 90 years old
- SOFA score of 2 points or higher
- Diagnosis of cardiac insufficiency in sepsis within 24 hours
- Patient or family member has signed informed consent
- Healthy subjects aged 50 to 90 years old, permanent residents of Beijing community
- Good health with no abnormalities in blood routine, liver and kidney function, blood lipids, or blood coagulation
- No diagnosis of cardiac insufficiency, acute coronary syndrome, old myocardial infarction, or cardiomyopathy
- No history of long-term use of drugs affecting platelet or coagulation function
- Willingness to cooperate with study procedures
- Subject has signed informed consent
You will not qualify if you...
- Diagnosis of acute coronary syndrome, old myocardial infarction, or coronary heart disease revascularization
- Cardiac insufficiency caused by cardiomyopathy such as hypertrophic, dilated, amyloidosis, diabetic, or hypothyroidic cardiomyopathy
- Cardiac insufficiency caused by structural abnormalities, arrhythmias, cor pulmonale, or nephroheart syndrome
- Severe primary diseases affecting survival, including uncontrolled metastatic malignant tumors, blood diseases, novel coronavirus infection, or HIV
- Liver or kidney dysfunction with a SOFA score of 3 or higher in those organs
- Use of immunosuppressants or history of organ transplantation in the past 6 months
- Use of corticosteroids equivalent to methylprednisolone ≥20mg/day for 7 consecutive days prior to enrollment
- Pregnant or lactating women
- Use or injection of drugs affecting platelet or coagulation function
- Participation in other clinical trials within 30 days prior to enrollment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
DongzhimenH，Beijing
Beijing, Beijing Municipality, China, 100700
Actively Recruiting
Research Team
Y
Yao Sheng Xiu
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here